Economic Evaluation of Natalizumab (Tysabri®) for the treatment of relapsing remitting multiple sclerosis that is rapidly evolving and severe or sub-optimally treated.
|January 2007||April 2007||Reimbursement recommended.|
Natalizumab could be considered borderline cost effective in the Irish healthcare setting. In view of the uncertainty surrounding some of the ICERs a follow up review is advised. The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.